vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v23i5.2802vsp-3595Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWЭффективность и безопасность применения пимекролимуса в лечении атопического дерматита у детейPimecrolimus Efficacy and Safety in Management of Children with Atopic Dermatitishttps://orcid.org/0000-0003-2252-8570МурашкинН. Н.MurashkinNikolay N.

Мурашкин Николай Николаевич, доктор медицинских наук, профессор, руководитель НИИ детской дерматологии, заведующий отделением дерматологии и аллергологии, заведующий лабораторией патологии кожи у детей отдела научных исследований в педиатрии;  профессор кафедры дерматовенерологии и косметологии; профессор кафедры педиатрии и детской ревматологии

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (495) 967-14-20

Moscow

m_nn2001@mail.ruhttps://orcid.org/0009-0003-5367-3268ПавловаЕ. С.PavlovaEkaterina S.

Москва

Moscow

https://orcid.org/0000-0002-4107-4642ЕпишевР. В.EpishevRoman V.

Москва

Moscow

https://orcid.org/0000-0002-6034-8231МатерикинА. И.MaterikinAlexander I.

Москва

Moscow

https://orcid.org/0000-0002-0081-0981ИвановР. А.IvanovRoman A.

Москва

Moscow

https://orcid.org/0000-0002-0858-8780ОпрятинЛ. А.OpryatinLeonid A.

Москва

Moscow

https://orcid.org/0000-0001-9777-0156ФедоровД. В.FedorovDmitriy V.

Москва

Moscow

https://orcid.org/0000-0001-5739-0941ЛеоноваМ. А.LeonovaMariya A.

Москва

Moscow

https://orcid.org/0000-0001-6884-5171СавеловаА. А.SavelovaAlena A.

Москва

Moscow

НМИЦ здоровья детей; Первый МГМУ им. И.М. Сеченова (Сеченовский Университет); ЦГМА УДП РФРоссияNational Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy of Department of Presidential AffairsRussian FederationНМИЦ здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian Federation202429102024235280284Copyright © Мурашкин Н.Н., Павлова Е.С., Епишев Р.В., Материкин А.И., Иванов Р.А., Опрятин Л.А., Федоров Д.В., Леонова М.А., Савелова А.А., 20242024Мурашкин Н.Н., Павлова Е.С., Епишев Р.В., Материкин А.И., Иванов Р.А., Опрятин Л.А., Федоров Д.В., Леонова М.А., Савелова А.А.Murashkin N.N., Pavlova E.S., Epishev R.V., Materikin A.I., Ivanov R.A., Opryatin L.A., Fedorov D.V., Leonova M.A., Savelova A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/3595

Атопический дерматит (АтД) — одно из наиболее распространенных воспалительных заболеваний кожи. Раннее лечение АтД необходимо для предотвращения развития заболеваний атопической природы, таких как астма, аллергический ринит и др. Топические глюкокортикоиды (ТГК) используются в качестве терапии первой линии, но их длительное применение представляет риск для здоровья пациента. Несмотря на быстрый клинический ответ при обострении кожного процесса, длительное применение ТГК в первой линии терапии сопровождается рядом нежелательных явлений, включающих атрофию кожи, подавление гипоталамо-гипофизарно-надпочечниковой оси, телеангиэктазии и др. Все это ограничивает долгосрочное применение ТГК, особенно при лечении пациентов детского возраста и использовании препарата в чувствительных зонах, таких как лицо и интертригинозные области. Из-за этих ограничений ТГК следует использовать только в течение короткого промежутка времени. Ограничения как по продолжительности лечения, так и по количеству применяемых препаратов делают ТГК неоптимальными для длительного лечения АтД. Пимекролимус (1% крем) является местным ингибитором кальциневрина, который показан для лечения АтД легкой и умеренной степени тяжести. Пимекролимус не вызывает выраженных побочных эффектов по сравнению с ТГК и хорошо переносится при длительном применении.

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases. Early management of AD is crucial for preventing the development of atopic disease such as asthma, allergic rhinitis, etc. Topical glucocorticoids (TGCs) are used as first-line therapy, however, their long-term use poses the risk for patient's health. Despite the rapid clinical response at skin process aggravation, long-term use of TGCs in first-line therapy is associated with various adverse events, including: skin atrophy, hypothalamic-pituitaryadrenal axis suppression, telangiectasis, etc. All together it limits the long-term TGCs use, especially in management of pediatric patients and using such drugs in sensitive regions such as face and intertriginous areas. Due to these limitations TGCs should only be used for a short period of time. Thus, limitations in both treatment duration and number of drugs make TGCs non-optimal for long-term AD treatment. Pimecrolimus (1% cream) is a topical calcineurin inhibitor that is indicated for the treatment of mild to moderate AD. Pimecrolimus does not cause any significant side effects compared to TGCs and it is well tolerated for long-term administration.

атопический дерматитпимекролимустопический ингибитор кальциневринатопические глюкокортикоидыatopic dermatitispimecrolimustopical calcineurin inhibitortopical glucocorticoidsОтсутствует.Not declared.ReferencesLangan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: https://doi.org/10.1016/s0140-6736(20)31286-1Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: https://doi.org/10.1016/s0140-6736(20)31286-1Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: https://doi.org/10.1038/s41572-018-0001-zWeidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: https://doi.org/10.1038/s41572-018-0001-zRaimondo A, Lembo S. Atopic Dermatitis: Epidemiology and Clinical Phenotypes. Dermatol Pract Concept. 2021;11(4): e2021146. doi: https://doi.org/10.5826/dpc.1104a146Raimondo A, Lembo S. Atopic Dermatitis: Epidemiology and Clinical Phenotypes. Dermatol Pract Concept. 2021;11(4): e2021146. doi: https://doi.org/10.5826/dpc.1104a146Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045–1060. doi: https://doi.org/10.1111/j.1468-3083.2012.04635.xRing J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045–1060. doi: https://doi.org/10.1111/j.1468-3083.2012.04635.xWatson W, Kapur S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):S4. doi: https://doi.org/10.1186/1710-1492-7-S1-S4Watson W, Kapur S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):S4. doi: https://doi.org/10.1186/1710-1492-7-S1-S4Barnetson RS, Rogers M. Childhood atopic eczema. BMJ. 2002;324:1376–1379. doi: https://doi.org/10.1136/bmj.324.7350.1376Barnetson RS, Rogers M. Childhood atopic eczema. BMJ. 2002;324:1376–1379. doi: https://doi.org/10.1136/bmj.324.7350.1376Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14): 1483–1494. doi: https://doi.org/10.1056/NEJMra074081Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14): 1483–1494. doi: https://doi.org/10.1056/NEJMra074081Paller A, Spergel J, Mina-Osorio P, Irvine A. The atopic march and atopic multimorbidity: Many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46–55. doi: https://doi.org/10.1016/j.jaci.2018.11.006Paller A, Spergel J, Mina-Osorio P, Irvine A. The atopic march and atopic multimorbidity: Many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46–55. doi: https://doi.org/10.1016/j.jaci.2018.11.006Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337–1343. doi: https://doi.org/10.1016/j.jaci.2008.01.022Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337–1343. doi: https://doi.org/10.1016/j.jaci.2008.01.022Lee HJ, Lee SH. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res. 2014;6(4):276–87. doi: https://doi.org/10.4168/aair.2014.6.4.276Lee HJ, Lee SH. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res. 2014;6(4):276–87. doi: https://doi.org/10.4168/aair.2014.6.4.276Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010;125(1):4–13. doi: https://doi.org/10.1016/j.jaci.2009.11.027Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010;125(1):4–13. doi: https://doi.org/10.1016/j.jaci.2009.11.027Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J Allergy Clin Immunol. 2014;133(6):1615–1625.e1. doi: https://doi.org/10.1016/j.jaci.2013.12.1079Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J Allergy Clin Immunol. 2014;133(6):1615–1625.e1. doi: https://doi.org/10.1016/j.jaci.2013.12.1079Hepburn D, Yohn JJ, Weston WI. Topical steroid treatment in infants, children, and adolescents. Adv Dermatol. 1994;9:225–255; discussion 255.Hepburn D, Yohn JJ, Weston WI. Topical steroid treatment in infants, children, and adolescents. Adv Dermatol. 1994;9:225–255; discussion 255.Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila). 2000;39(1):1–14. doi: https://doi.org/10.1177/000992280003900101Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila). 2000;39(1):1–14. doi: https://doi.org/10.1177/000992280003900101Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Investig Dermatol. 1952;19(2):101–102. doi: https://doi.org/10.1038/jid.1952.72Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Investig Dermatol. 1952;19(2):101–102. doi: https://doi.org/10.1038/jid.1952.72Marshall HF, Leung DYM, Lack G, et al. Topical steroid withdrawal and atopic dermatitis. Ann Allergy Asthma Immunol. 2023;132(4):423–425. doi: https://doi.org/10.1016/j.anai.2023.12.022Marshall HF, Leung DYM, Lack G, et al. Topical steroid withdrawal and atopic dermatitis. Ann Allergy Asthma Immunol. 2023;132(4):423–425. doi: https://doi.org/10.1016/j.anai.2023.12.022Maghen P, Unrue EL, Oussedik E, et al. Regardless of how risks are framed, patients seem hesitant to use topical steroids for atopic dermatitis. Br J Dermatol. 2019;181(4):842–844. doi: https://doi.org/10.1111/bjd.17929Maghen P, Unrue EL, Oussedik E, et al. Regardless of how risks are framed, patients seem hesitant to use topical steroids for atopic dermatitis. Br J Dermatol. 2019;181(4):842–844. doi: https://doi.org/10.1111/bjd.17929Gutfreund K, Bienias W, Szewczyk A, Kaszuba A. Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Postep Dermatol Alergol. 2013;30(3): 165–169. doi: https://doi.org/10.5114/pdia.2013.35619Gutfreund K, Bienias W, Szewczyk A, Kaszuba A. Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Postep Dermatol Alergol. 2013;30(3): 165–169. doi: https://doi.org/10.5114/pdia.2013.35619Luger T, Augustin M, Lambert J, et al. Unmet medical needs in the treatment of atopic dermatitis in infants: an expert consensus on safety and efficacy of Pimecrolimus. Pediatr Allergy Immunol. 2021;32(3):414–424. doi: https://doi.org/10.1111/pai.13422Luger T, Augustin M, Lambert J, et al. Unmet medical needs in the treatment of atopic dermatitis in infants: an expert consensus on safety and efficacy of Pimecrolimus. Pediatr Allergy Immunol. 2021;32(3):414–424. doi: https://doi.org/10.1111/pai.13422Hanna S, Zip C, Shear NH. What is the risk of harm associated with topical calcineurin inhibitors? J Cutan Med Surg. 2019;23(4_suppl):19S–26S. doi: https://doi.org/10.1177/1203475419857688Hanna S, Zip C, Shear NH. What is the risk of harm associated with topical calcineurin inhibitors? J Cutan Med Surg. 2019;23(4_suppl):19S–26S. doi: https://doi.org/10.1177/1203475419857688Shin N, Jung N, Lee SE, et al. Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling. Stem Cell Res Ther. 2021;12(1):482. doi: https://doi.org/10.1186/s13287-021-02547-8Shin N, Jung N, Lee SE, et al. Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling. Stem Cell Res Ther. 2021;12(1):482. doi: https://doi.org/10.1186/s13287-021-02547-8Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597–606. doi: https://doi.org/10.1542/peds.2014-1990Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597–606. doi: https://doi.org/10.1542/peds.2014-1990Luger T, De Raeve L, Gelmetti C, et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur J Dermatol. 2013;23(6):758–766. doi: https://doi.org/10.1684/ejd.2013.2169Luger T, De Raeve L, Gelmetti C, et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur J Dermatol. 2013;23(6):758–766. doi: https://doi.org/10.1684/ejd.2013.2169Nuutinen P, Riekki R, Parikka M, et al. Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. Br J Dermatol. 2003;148(1):39–45. doi: https://doi.org/10.1046/j.1365-2133.2003.05018.xNuutinen P, Riekki R, Parikka M, et al. Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. Br J Dermatol. 2003;148(1):39–45. doi: https://doi.org/10.1046/j.1365-2133.2003.05018.xGrassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus — an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004;13(12):721–730. doi: https://doi.org/10.1111/j.0906-6705.2004.00269.xGrassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus — an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004;13(12):721–730. doi: https://doi.org/10.1111/j.0906-6705.2004.00269.xKyllönen H, Remitz A, Mandelin JM, et al. Effect of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol. 2004;150(6):1174–1181. doi: https://doi.org/10.1111/j.1365-2133.2004.06017.xKyllönen H, Remitz A, Mandelin JM, et al. Effect of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol. 2004;150(6):1174–1181. doi: https://doi.org/10.1111/j.1365-2133.2004.06017.xSigurgeirsson B, Ho V, Ferrandiz C, et al. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(11):1290–1301. doi: https://doi.org/10.1111/j.1468-3083.2008.02785.xSigurgeirsson B, Ho V, Ferrandiz C, et al. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(11):1290–1301. doi: https://doi.org/10.1111/j.1468-3083.2008.02785.xGollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol. 2008;158(5):1083–1093. doi: https://doi.org/10.1111/j.1365-2133.2008.08484.xGollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol. 2008;158(5):1083–1093. doi: https://doi.org/10.1111/j.1365-2133.2008.08484.xRuer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2009;26(5):551–558. doi: https://doi.org/10.1111/j.1525-1470.2009.00981.xRuer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2009;26(5):551–558. doi: https://doi.org/10.1111/j.1525-1470.2009.00981.xKapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002;110(2): 277–284. doi: https://doi.org/10.1067/mai.2002.126500Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002;110(2): 277–284. doi: https://doi.org/10.1067/mai.2002.126500Lübbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol. 2003;4(9):641–654. doi: https://doi.org/10.2165/00128071-200304090-00006Lübbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol. 2003;4(9):641–654. doi: https://doi.org/10.2165/00128071-200304090-00006Leung DY. Infection in atopic dermatitis. Curr Opin Pediatr. 2003;15(4):399–404. doi: https://doi.org/10.1097/00008480-200308000-00008Leung DY. Infection in atopic dermatitis. Curr Opin Pediatr. 2003;15(4):399–404. doi: https://doi.org/10.1097/00008480-200308000-00008Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850–859. doi: https://doi.org/10.1101/gr.131029.111Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850–859. doi: https://doi.org/10.1101/gr.131029.111Luger TA, Lahfa M, Fölster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat. 2004;15(3):169–178. doi: https://doi.org/10.1080/09546630410033781Luger TA, Lahfa M, Fölster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat. 2004;15(3):169–178. doi: https://doi.org/10.1080/09546630410033781Lübbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7(2):121–131. doi: https://doi.org/10.2165/00128071-200607020-00005Lübbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7(2):121–131. doi: https://doi.org/10.2165/00128071-200607020-00005Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2. doi: https://doi.org/10.1542/peds.110.1.e2Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2. doi: https://doi.org/10.1542/peds.110.1.e2Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin. 2008;24(4):985–994. doi: https://doi.org/10.1185/030079908X280419Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin. 2008;24(4):985–994. doi: https://doi.org/10.1185/030079908X280419Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15. doi: https://doi.org/10.1016/j.jaad.2005.01.010Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15. doi: https://doi.org/10.1016/j.jaad.2005.01.010Plotz SG, Ring J. What’s new in atopic eczema? Expert Opin Emerg Drugs. 2010;15(2):249–267. doi: https://doi.org/10.1517/14728211003792518Plotz SG, Ring J. What’s new in atopic eczema? Expert Opin Emerg Drugs. 2010;15(2):249–267. doi: https://doi.org/10.1517/14728211003792518Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–417. doi: https://doi.org/10.1016/j.jaci.2005.10.033Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–417. doi: https://doi.org/10.1016/j.jaci.2005.10.033Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984–992. doi: https://doi.org/10.1111/j.1742-1241.2006.01047.xLewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984–992. doi: https://doi.org/10.1111/j.1742-1241.2006.01047.xMatterne U, Böhmer MM, Weisshaar E, et al. Oral H1 antihistamines as ‚add-on‘ therapy to topical treatment for eczema. Cochrane Database Syst Rev. 2019;1(1):CD012167. doi: https://doi.org/10.1002/14651858.CD012167.pub2Matterne U, Böhmer MM, Weisshaar E, et al. Oral H1 antihistamines as ‚add-on‘ therapy to topical treatment for eczema. Cochrane Database Syst Rev. 2019;1(1):CD012167. doi: https://doi.org/10.1002/14651858.CD012167.pub2Whalley D, Huels J, McKenna SP, van Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on quality of life in the treatment of paediatric atopic dermatitis. Pediatrics. 2002;110(6): 1133–1136. doi: https://doi.org/10.1542/peds.110.6.1133Whalley D, Huels J, McKenna SP, van Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on quality of life in the treatment of paediatric atopic dermatitis. Pediatrics. 2002;110(6): 1133–1136. doi: https://doi.org/10.1542/peds.110.6.1133

The authors declare that there are no conflicts of interest present.